Nature Communications (Apr 2022)
Ubiquitin ligase STUB1 destabilizes IFNγ-receptor complex to suppress tumor IFNγ signaling
- Georgi Apriamashvili,
- David W. Vredevoogd,
- Oscar Krijgsman,
- Onno B. Bleijerveld,
- Maarten A. Ligtenberg,
- Beaunelle de Bruijn,
- Julia Boshuizen,
- Joleen J. H. Traets,
- Daniela D’Empaire Altimari,
- Alex van Vliet,
- Chun-Pu Lin,
- Nils L. Visser,
- James D. Londino,
- Rebekah Sanchez-Hodge,
- Leah E. Oswalt,
- Selin Altinok,
- Jonathan C. Schisler,
- Maarten Altelaar,
- Daniel S. Peeper
Affiliations
- Georgi Apriamashvili
- Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute
- David W. Vredevoogd
- Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute
- Oscar Krijgsman
- Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute
- Onno B. Bleijerveld
- Proteomics Core Facility, The Netherlands Cancer Institute
- Maarten A. Ligtenberg
- Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute
- Beaunelle de Bruijn
- Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute
- Julia Boshuizen
- Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute
- Joleen J. H. Traets
- Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute
- Daniela D’Empaire Altimari
- Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute
- Alex van Vliet
- Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute
- Chun-Pu Lin
- Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute
- Nils L. Visser
- Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute
- James D. Londino
- Division of Pulmonary, Critical Care and Sleep Medicine, The Ohio State University Wexner Medical Center
- Rebekah Sanchez-Hodge
- McAllister Heart Institute and Department of Pharmacology, The University of North Carolina at Chapel Hill
- Leah E. Oswalt
- McAllister Heart Institute and Department of Pharmacology, The University of North Carolina at Chapel Hill
- Selin Altinok
- McAllister Heart Institute and Department of Pharmacology, The University of North Carolina at Chapel Hill
- Jonathan C. Schisler
- McAllister Heart Institute and Department of Pharmacology, The University of North Carolina at Chapel Hill
- Maarten Altelaar
- Proteomics Core Facility, The Netherlands Cancer Institute
- Daniel S. Peeper
- Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute
- DOI
- https://doi.org/10.1038/s41467-022-29442-x
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 16
Abstract
The IFNγ response pathway is associated with response to immunotherapy in cancer. Here the authors show that high levels of the IFNγ-receptor (IFNγ-R1) affect the outcome of immunotherapy in a context-dependent fashion and identify the E3 ubiquitin ligase STUB1 as a negative regulator of IFNγ-R1/JAK1 expression in cancer cells.
